COVID-19 treatment

Major U.S. trial closes showing no benefit for hydroxychloroquine in COVID-19

The Outcomes Related to COVID-19 Treated with Hydroxychloroquine among In-patients with Symptomatic Disease (ORCHID) trial stopped enrolling new patients based on the fourth scheduled interim analysis showing no evidence of benefit or harm. 

TERAVOLT registry tracks outcomes of treatments among people with thoracic cancers sickened by COVID-19

New data from TERAVOLT, a global consortium that tracks outcomes of people with thoracic cancers affected by COVID-19, offers clues as to why they experienced a high death rate of 33% when the coronavirus swept across Europe.

Vanderbilt, AstraZeneca collaborate on new COVID-19 antibody research

After evaluating the ability of more than 1,500 monoclonal antibodies to bind and neutralize the COVID-19 virus, SARS-CoV-2, in the laboratory, AstraZeneca signed an exclusive license to six candidate antibodies in Vanderbilt’s portfolio.

Remdesivir helps reduce COVID-19 recovery time: study

The investigational antiviral drug remdesivir can shorten the time to recovery in adults hospitalized with COVID-19, according to preliminary results of a clinical trial published last month in The New England Journal of Medicine.

Multinational consortium reports COVID-19 impact on cancer patients

People with cancer sickened by COVID-19 have a crude death rate of 13%, according to the largest series of data released thus far from a multinational perspective. The data on more than 900 patients, published May 28 in The Lancet and simultaneously presented at ASCO20 Virtual, also revealed cancer-specific factors associated with increased mortality.

Scenes from the pandemic, collection three: glimpses into life during COVID-19 at Vanderbilt

As Vanderbilt continues to care for COVID-19 patients, other care, including clinic visits and elective surgeries, begin again.

1 7 8 9 10 11 12